Back to companies

Poseida Therapeutics Inc: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Poseida Therapeutics Inc (Poseida Therapeutics), a subsidiary of Roche Holding AG, is a clinical-stage biopharmaceutical company that focuses on developing cell and gene therapies. Its activities leverage proprietary non-viral gene engineering technologies to create innovative cell and gene therapies. Poseida Therapeutics' product pipeline includes P-PSMA-ALL01 and P-MUC1C-ALLO1 for the treatment of solid tumors. Poseida Therapeutics other pipeline products include P-BCMA-ALLO1, P-BCMACD19-ALLO1, P-CD19CD20-ALLO1, and P-CD70-ALLO1 for the treatment of hematologic malignancies and autoimmune diseases. It also develops several liver-directed gene therapies comprising KLKB1-101 and P-FVIII-101. The company works in partnership with Roche and Astellas. Poseida Therapeutics is headquartered in San Diego, California, the US.

 Gain a 360-degree view of Poseida Therapeutics Inc and make more informed decisions for your business Gain a 360-degree view of Poseida Therapeutics Inc and make more informed decisions for your business Register your interest
Headquarters United States of America
Address Suite 200, 9390 Towne Centre Drive, San Diego, California, 92121
Website www.poseida.com
Telephone 1 858 7793100
No of Employees 350
Industry Pharmaceuticals and Healthcare
Revenue (2023) $64.7M
   
   
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Register your interest

Poseida Therapeutics Inc premium industry data and analytics

40+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Poseida Therapeutics Inc’s relevant decision makers and contact details.

20+

Pipeline Drugs

Identify which of Poseida Therapeutics Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

20+

Catalyst Calendar

Proactively evaluate Poseida Therapeutics Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

6

Clinical Trials

Determine Poseida Therapeutics Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

2

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

Products and Services

Products
Pipeline
Solid Tumors:
P-MUC1C-ALLO1
XYZ
XYZ
XYZ
Understand Poseida Therapeutics Inc portfolio and identify potential areas for collaboration Understand Poseida Therapeutics Inc portfolio and identify potential areas for collaboration Register your interest

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2025 Ownership Changes In January, the company was acquired by Roche.
2024 Regulatory Approval In September, the company secured the Regenerative Medicine Advanced Therapy designation from the US Food and Drug Administration for its investigational stem cell memory (TSCM) T cell-based allogeneic CAR [chimeric antigen receptor]-T cell therapy, P-BCMA-ALLO1.
2024 Contracts/Agreements In May, the company signed an agreement with Xyphos Biosciences, Inc. to develop groundbreaking convertible CAR programs, leveraging the innovative cell therapy platforms of both companies.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Register your interest
Image for loader

Competitor Comparison

Key Parameters Poseida Therapeutics Inc Merck & Co Inc Pfizer Inc AstraZeneca Plc Novartis AG
Headquarters United States of America United States of America United States of America United Kingdom Switzerland
City San Diego Rahway New York City Cambridge Basel
State/Province California New Jersey New York Cambridgeshire Basel-Stadt
No. of Employees 350 75,000 75,000 96,100 75,267
Entity Type Private Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Register your interest
Executives
Name Position Board Since Age
Kristin Yarema, Ph.D. Chief Executive Officer Senior Management - -
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Poseida Therapeutics Inc key executives to enhance your sales strategy Gain insight into Poseida Therapeutics Inc key executives to enhance your sales strategy Register your interest
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?